NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled
NCT02947165 2022-01-31Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.NovartisPhase 1 Completed120 enrolled